Mentions
Extended reach
Total likes
Video views
AI synopsis
The collection reveals a tense debate where many posts emphasize flaws or potential misconduct, using words like 'pseudoscience,' 'fraud,' and 'rigged,' indicating distrust and a dismissive tone. Some posts acknowledge the study’s findings of shorter recovery times but highlight doubts about mortality benefits, reflecting mixed engagement with the research's significance and implications.
The overall tone shows skepticism and disagreement with the article's findings, with many posts claiming that the study is flawed or manipulated.
There is moderate interest, as users are engaging with the details of the study and related trials but often express doubt or dismissiveness.
The posts mainly share opinions, references, and critiques rather than in-depth analysis or active debate.
Discussions suggest that the publication influences some skepticism around remdesivir but does not seem to drive widespread consensus or policy change.
Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median 11 vs 15 days w/placebo) in COVID patients with pulmonary involvement. 9/n https://t.co/hz8It1DmcJ
【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発表を期待してます https://t.co/XpSjs17UDD
In #ACTT1 RDV did improve outcomes on an ordinal scale, but the effect was modest. It shortened time to clinical improvement but not hospital LOS (patients stayed in the hospital longer to receive it). RDV did NOT improve mortality or risk of IMV. https://t.co/yGseeo3dNd 3/ https://t.co/D8If31k9Kv
brilliant video on remdesiver by @DrEricStrong. Great production and clear explanations. https://t.co/Qw873tsN5w
3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demostrado ser eficaz en pacientes que requieren oxígeno suplementario, reduciendo la mortalidad y la convalecencia de 15 a 11 días.
Ter info aan alle politici die plots zelfverklaarde Remdivisir-specialisten zijn geworden: misschien dit even lezen ipv HLN? https://t.co/2nA9PLccCu
This video examines how remdesivir works against COVID-19 and reviews key clinical trial results showing it shortens recovery time and improves patient outcomes, with a focus on safety and efficacy.
The RTPCR test does not definitively indicate COVID-19 infection. This analysis scrutinizes the Solidarity trial's findings and highlights that hydroxychloroquine showed no significant benefit in treatment outcomes…
COVID-19 has caught up with President Donald Trump, highlighting the importance of safety measures. Vitamin D sufficiency, with levels at least 30 ng/mL, significantly reduces severe outcomes in COVID-19, suggesting…
This video discusses the differences between COVID-19 vaccines and treatments. It highlights the global effort to find effective therapies like the REGN-COV2 antibody cocktail, which shows promise in reducing virus…
Seroprevalence of almost 30 in Delhi suggests infection fatality rate is as low as 0.06. A significant decline in new cases indicates progress towards herd immunity, with strong T cell responses playing a key role in…
A global effort is underway to find effective treatments for COVID-19, focusing on the antibody cocktail REGN-COV2. This video explores how REGN-COV2 significantly reduces virus levels in animal models, providing…
This video explores the probable molecular mechanism of remdesivir in treating COVID-19, focusing on its potential to inhibit SARS-CoV-2 RNA synthesis. Further research is necessary to fully understand and enhance its…
The RECOVERY trial investigated effective COVID-19 treatments. Remdesivir significantly reduced median recovery time from 15 to 10 days and improved clinical outcomes, showing it is a safe and more effective option for…
@ChadVanderSchu1 @Lost_Spaniard @karma44921039 Here is multiple articles explaining Remdesivir 10x more accurately than this pseudoscience spouting fear inducing asshole in the video you cited https://t.co/eBxT1cP627 https://t.co/pyLfV5zR08
@Humanspective why post this crap? The reasoning and adjustments are clearly explained in the study. Pts remained blinded, results unaffected. Still significant improvement. (Siri also fails to mention metanalyses showing benefit). https://t.co/d7in9keYph
Remdesivir for the Treatment of Covid-19 — Final Report | New England Journal of Medicine https://t.co/Dzsjc0bn8U #Remdesivir better than placebo in outcomes #SarsCov2 @humansp
@SOCALEASTCOAST @DrNeilStone https://t.co/yDRRHcUq5V
RT @fujiokashinya: John H. Beigel, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020; 383: 1813-1826 https…
RT @HELEN88811: Remdesivir for the Treatment of Covid-19 — Final Report List of authors. John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H…
@HeyNurseKat @LisaAirey888 @DiedSuddenly_ RFKjr not scientist, he doesn’t need to be. Covid is nonexistent communicable disease nobody so they used Remdisivir infusion to cause renal failure to multi organ failures used to kill people to be counted as died of Covid. https://t.co/NHigO4dqIn
@AbigailMal92836 @a22095_sam @DiedSuddenly_ If Covid survival rate 99% it’s never been pandemic. Nobody died of Covid. People falsely positive of Covid go to ER, admitted, put on NIH so-called treatment protocol 10 days Remdisivir infusion, people died of multi organ failures. Remdisivir is poison. https://t.co/NHigO4dqIn
RT @DrLalibrahim: دراسة حديثة نشرت عن دواء Remdesivir في علاج #كورونا بمجلة https://t.co/gcK5Yt1Sq2? ملخص الدراسة أن العقار يقلل مدة الإصاب…
@IRMAARetirement Study 4: "remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection." https://t.co/DRBGVp6UtS
@Danielthmanyall @25_cycle @simonmaechling volunteers. Reference: Beigel JH et al., NEJM 2020 — ACTT-1 trial: https://t.co/3npTCy7CjH Ventilation: Early pandemic ventilator protocols were imperfect, but no credible evidence shows a systematic “ventilate to death” policy. Treatment guidance evolved with evidence.
@Earl_R_Robinson @julie4butte5 17B/ https://t.co/iGflbP7FNz https://t.co/yYewrsYRyx
@Earl_R_Robinson @julie4butte5 11B/ Ref: https://t.co/yYewrsYRyx https://t.co/w6Ptk903hc
@DawsonInga @_LUZID @HouseLyndseyRN Beigel JH, et al. Remdesivir for Covid-19—Final Report. NEJM 2020;383:1813–26. doi:10.1056/NEJMoa2007764. PMID: 32445440. Amstutz A, et al. Remdesivir: systematic review & IPD meta-analysis of RCTs. Lancet Respir Med 2023. doi:10.1016/S2213-2600(22)00528-8. PMID: 36828006.
@DawsonInga @_LUZID @HouseLyndseyRN Myth check: “Remdesivir killed COVID pts.” Reality: ACTT-1 RCT → faster recovery (10 vs 15 days) when started early in hospitalized pts on O₂; mortality trended lower. Antivirals work when used early. (NEJM 2020; doi:10.1056/NEJMoa2007764)
@Davis23667Davis @danparker55 @wideawake_media Oh https://t.co/GyR4HKmXBr
@wideawake_media I'm not a data scientist but below is the study that was used to approve remdesivir. It puports to prove 'shorter time to recovery'. Ask yourself this, why not prove "LOWER MORTALITY RATE"? Because it doesn't prove to lower the mortality rate, that's why. https://t.co/XbP8rPX1So
@icthruyou2 @liles_larry @ChrisPatterDu @jakescottMD This one show to slight improvement amongst those patients who receive Remdesivir. "remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection." https://t.co/DRBGVp6UtS
@DerOfDuty @goddessraelinn @carlwaring @DrNeilStone As a start, the initial ACCT-1 trial found remdesivir cut recovery time by a third, and there were less severe adverse events in the treated group than the placebo group. https://t.co/xwYlDFMJN0
RT @IanSolliec: @sudokuvariante Death was removed as a primary outcome after patients had already enrolled. The authors of the final report…
@sudokuvariante Death was removed as a primary outcome after patients had already enrolled. The authors of the final report justify the increased duration of the time-frame, but not the removal of clinical status including death from outcome measures. Link to the report: https://t.co/GU7TNUYWV7 https://t.co/m7MdFDiZjF
@HeIsGR8Rdeni @DrNeilStone “A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days as compared with 15 days among those who received placebo.” https://t.co/YffXWb8gC4
@pjd77420 @Olivierfente Une étude frauduleuse menée par le NIH/NIAID de Fauci pour obtenir l'approbation du Remdesivir est également apparue dans le NEJM intitulée « Remdesivir pour le traitement du C19 - Rapport final » . Il a été financé par le fabricant du Remdesivir, Gilead. https://t.co/oSwaNMxcxy
@davideyoungmd @stevesnewday @MdBreathe What was the placebo? Seems sort of important so you know what you are comparing. Was it this study?
@davideyoungmd @stevesnewday @MdBreathe Look at their data. They had significantly more people in more severe conditions for the placebo group and the death rate you quoted was for two weeks. After 4 the difference was much smaller https://t.co/4VVGv3CtM3
@Hohounk @stevesnewday @MdBreathe Her is the phase III registration trial that led to the approval of Remdesivir. https://t.co/Sp3f2Wnp8H
Remdesivir for the Treatment of Covid-19 — Final Report | New England Journal of Medicine www.nejm.org/doi/10.1056/...
@HealthNutDSc @NicHulscher While we can argue how helpful remdesivir was, it did not increase death rates. https://t.co/OscyW7UOec
RT @atranscendedman: @terrorbird83 this suggests the opposite. sorry for your losses! https://t.co/tZGkAAIyey
@terrorbird83 this suggests the opposite. sorry for your losses! https://t.co/tZGkAAIyey
@jcat81516 @DawnsMission https://t.co/uZfyoyc0mu and from 500?
@angie_rasmussen One can see it's not true Fauci suppressed trials of ivermectin because if it worked vaccine approval would be hindered - by noting NIAID funded a trial of Remdesivir, which found it worked (it took more trials, but Remdesivir effectiveness is confirmed). https://t.co/0OojePGliw
@DavidLHagen @EthicalSkeptic That's also wrong. https://t.co/u4jjjWYvuM https://t.co/rtD45nefhx
@liz_churchill10 Multiple organ failure is secondary to Ebola virus- need source on causal relationship to Remdesivir. Covid studies on the drug: https://t.co/J3VJxFHaAl https://t.co/NeoEgfQZfx
@JoJoMaxwell1 @CarolsCloset @FLSurgeonGen @CDCgov @DrHarveyRisch https://t.co/w8H9FtWPYi
I wonder how much they were paid to publish this garbage? Remdesivir for the Treatment of Covid-19 — Final Report | New England Journal of Medicine https://t.co/2SCjuCI04U
@ModChristChurch @cafelockedout https://t.co/rHpOzgMlM1
@mothrfunkr @Creativologist @NassMeryl Clinical trials show Remdesivir works. https://t.co/eFoyNmUPWG It's not for everyone. Those with impaired liver function should probably avoid it, for example. That's why you make decisions like this with your doctor.
RT @daniel_corcos: Le Remdesivir, très coûteux et toxique pour les reins n'avait pas grande chance dans cette compétition mais a bénéficié…
Le Remdesivir, très coûteux et toxique pour les reins n'avait pas grande chance dans cette compétition mais a bénéficié très rapidement d'un essai clinique suffisamment favorable https://t.co/tup5jXyxba pour justifier son utilisation. 5/
@GijjjIkke @unapologetic_47 Remdesivir has been proven to improve recovery from COVID-19. The following link is from the New England Joual of Medicine; https://t.co/HkIVOscxFW
@JediMasterCoggy @Debunk_the_Funk @RWMaloneMD @drsimonegold https://t.co/v6b3xQe6PY https://t.co/LhVVTvvpXw
@mothrfunkr @robertclose124 @loscharlos @patientled @LongCovidSOS @long_covid @LongCOVIDPhysio @LongCovidKids @C19LH_Advocacy @MEActNet @Dysautonomia @PlzSolveCFS @CDCgov Hon, you’re the one who doesn’t recognize stuff that he’s posted. But keep flailing. Oh, yes, since you prefer RCTs to real-world studies… https://t.co/v6b3xQe6PY https://t.co/Oo6kqg4ZNy
@TheRoseCompany Do you not believe in science? Like when you see The New England Journal of Medicine studies, do you just think, "nah"? https://t.co/fgFWbDtJHC
@MicrobiomDigest @gcabanac What about when the scientific literature has been contaminated by the US DoD? https://t.co/hPD72Lz3qU https://t.co/ZgUNkqajmc https://t.co/Dp6nlwvJpU https://t.co/tup5jXyxba
Yet, NIH-funded trials like ACTT already share data globally, with participants & ethics committees informed about it upfront. #COVID19 #DataTransparency https://t.co/nj8pblWwXX
@WilliamDoc51 @ChildrensHD @DrJudyAMikovits @PollyTommey Here’s a good place to start on this med: https://t.co/y6iDrdCH1A
RT @PeterLeversha: @myletrinh123 Have a look at this remdisivir trial. Now if your testing a drug for effectiveness against a disease, why…
@myletrinh123 Have a look at this remdisivir trial. Now if your testing a drug for effectiveness against a disease, why would enrol people with other serious conditions? Wouldn't you want normally healthy subjects? Source: https://t.co/ZJOs8mR0H5 https://t.co/TOYQPWTJvq
https://t.co/3C2OcBfJeI 2020
https://t.co/YAQsgQ9GaU
@Ccat4u2 @PriDFar1 @RepRobertGarcia I may have misunderstood your post. Wasn't Remdesevir helpful? https://t.co/XJCCNPpLtk
RT @davidnelsonORL: @DawnsMission @alanlremick So you ask for a study, but when given an example, you decide that one's not good enough. Ok…
@DawnsMission @alanlremick So you ask for a study, but when given an example, you decide that one's not good enough. Ok. Here's another. (and, btw, you can actually Google this yourself - there's a lot of legitimate studies) https://t.co/XoWgog8V4v
@DawnsMission You do know that the patients don't die from Remdesivir, right? Remdesivir shortens hospital time for patients with Covid. Here's the peer-reviewed study about it. https://t.co/YYdX2HNbF5
@nuhope2022 @KinseyKat1 @VickiCoyle10019 @J91U17 @karleastlondon @zee_parody @cbeckj @saltbeefsandwch @ASchifty @ogilville1 @TonyBaduy @JimeeLiberty @sduncanhealth @lavalmxhr @KuikenAndrew @Veeteejay1 @PlatoonOps @Pouldeau61 @BurgerLab12 @nickowe49445250 @doom37455413 @jilel76 @RealJonTSmith @Agent2Dark @epigeneticallyj @mcfunny @Scary7Dr @TheeLoneGunmen @dirk_fasshauer @orwelleye @JKelleyK @villagerssn @NexusSwords @ScooterScience @swords_mr @JordanScottish @IndyTim40 @eanstrainserver @lazlowoodbine42 @LummHandy @MaureenStroud @WendyOrent @ptcjoneses @JohnTho55144371 @Monstercoyliar @dann58638436 @DrSusanOliver1 @stkirsch I’m not going through this again. https://t.co/ZKJq6PKGCn
@Bithiah333 @rw_christian @ENirenberg @DowdEdward The New England Journal of Medicine. Ever heard of it. "Those who received remdesivir had a median recovery time of 10 days as compared with 15 days among those who received placebo." https://t.co/DRBGVp7sjq
@DrPickleRM @DawnsMission https://t.co/ZvZwqohIcq
@DawnsMission https://t.co/GCzoUH7Etu
@Ambergirl72 @Rotelli_MD A parte che non è vero, ma lo sai che non esistono farmaci che funzionino decentemente per il covid, vero? Funzionicchiano appena farmaci antivirali di ultima generazione, come il remdesivir... https://t.co/iRQlhk0uNg Studiate un po', porca trota!
@censorship_suks @sjs856 @DiedSuddenly_ https://t.co/v6b3xQeEFw https://t.co/BKI00eHl5r
@NoeticCosmos @JordanA8156 @gigsupman @faintheartedfem @p_beejal @robertopaulos85 1. Yeah it did. https://t.co/fjWx6hYxnt And still does. https://t.co/iYS20npAvl 2. Not proven. 3. MV is a well documented intervention for ARDS. So no, its clearly far more nuanced than that.
@Babydoll921961 @Debunk_the_Funk https://t.co/w8H9FtWPYi
@KatieGr37959419 @porterguy1 Actually it has been shown to help. Claiming that it kills is just propaganda from people who want to pretend that COVID wasn’t bad. https://t.co/w8H9FtWPYi
@neorevolt @SquawkCNBC https://t.co/3kEBl96Jxw
@darkandcrude @_Extirpator https://t.co/9ng0g9lTZp
@DoctorHussain96 @dhruv_rathee https://t.co/9ng0g9lTZp
@Babydoll921961 @SabinehazanMD @DrJackieStone It is clear you didn’t read the paper. It doesn’t support your claims. Here is another one. https://t.co/wbOq8YuMzr
@Icoronamae @BenMarble_MD @CHBMPorg Heres the report on the registration trial. https://t.co/ioP6SjpZu9
@Princes29423698 @Sassafrass_84 Remdesivir, superior to placebo….aka, not killing. https://t.co/jCiJEVVh7f
@Patriot20246023 @kaylamellis_ How about a multinational consortium performing a double-blind, randomized, placebo-controlled trial? https://t.co/X5dVfNsNOd
@PattyWantsTruth @ChildrensHD nope. I am not the one believing propaganda. https://t.co/hzmaQeUi4D
@Sarita_CaliGirl @ChildrensHD information https://t.co/hzmaQeUi4D
@FarshidV74 @HerbsandDirt https://t.co/sOUP3l7thu
@Blondie721 @HerbsandDirt More like approaching infinity the number of studies that show the opposite of your erroneous claims. https://t.co/rjoRLsqoZ4
@rob1098765 @NickHudsonCT *Sigh* - none of these trials show an increased risk of death: https://t.co/7tejuk4q7E https://t.co/vK4GH1mZ3J https://t.co/HuNxhLx11J
RT @ENirenberg: COVID has literally been “let’s rediscover all the fundamental principles of infectious disease once more” and we literally…
COVID has literally been “let’s rediscover all the fundamental principles of infectious disease once more” and we literally saw this play out in real time. E.g. Remdesivir in hospitalized patients? Equivocal mortality benefit, shorter hospitalization: https://t.co/vjGtsTu77V
@swani741 @davideyoungmd @P_McCulloughMD @delbigtree @ICANdecide @Jo_Bond @ChildrensHD https://t.co/X5dVfNsfYF
@NOmasCNE @weiner1962 @rubrogram Here is the registration trial for Remdesivir. Randomizing Remdesivir to placebo in hospitalized patients with COVID. There were FEWER cases of renal failure in those getting Remdesivir compared to placebo. https://t.co/ioP6SjpZu9
@AndreJ97721619 @VigilantFox https://t.co/ZpvAKuVmdR
RT @laworcester: @VigilantFox https://t.co/vnTwZiPDyn
@SumthinWhittee @Grandma04242012 @mtioran @VigilantFox https://t.co/ZpvAKuUOoj
@FluoridePoison @VigilantFox https://t.co/ZvZwqohIcq
@65MarkAnthony @VigilantFox https://t.co/ZvZwqohIcq
@potatohead_812 @VigilantFox Hmm. A proven treatment... https://t.co/ZvZwqohIcq
@gadsden_guy @VigilantFox @WilliamQ45A https://t.co/ZvZwqohIcq
RT @laworcester: @VigilantFox https://t.co/vnTwZiPDyn
RT @laworcester: @VigilantFox https://t.co/vnTwZiPDyn
RT @laworcester: @VigilantFox https://t.co/vnTwZiPDyn
@VigilantFox https://t.co/vnTwZiPDyn
https://t.co/foZefkoYun
@HamHead5813 @Bonbonhamilton @DavidLMayhew @PenOfAPisces @paramaniac9 @zwergie1 @PChandr43659403 @djchicus @dirk_fasshauer @1984rebooted @ImAtSeaAgain @ValZimmer2 @ThomMohr @ThePixelChick70 @DocDeezWhat @DoubleDumas @JohnTho55144371 @TakethatCt @JesperKitos @JimeeLiberty @LummHandy @sunshine_toes @ThroneOfCrypto @IMudlet @hauxton @MichelleZeh1968 @JRJHealey @ZeroPointV1 @catsequalneko @ScooterScience @cnv_cnvl @dan_gadd @pjholloway @PamelaE83716920 @SynthIge @CarlSmytheCells @Tetrahydropyran @BoyScou84038220 @ViroLIEgy @OB1_Benobie @arrdeearr @DiscernHeal @DdkDav @canceledmouse @SamolejJ @RightHandWatch @rw_christian @PrimalDaoist @niswarth @macgyvertang20 Funny none of this toxicity ever turned up in the clinical trials or assessments. https://t.co/oKOXlmW6IC
@ReidSheftallMD You can’t defend anything you say here. Remdesivir reduced mortality by from 15% to 11%. Oxygen days were cut from 21 to 13 d, recovery from 15 to 10 d. There was NO increased renal damage in the remdesivir group. https://t.co/ZaVZl6tvoG
@SharonandGlenn @dralexpatel @komradeperogie @drdagly The Covid trial is rather more relevant, wouldn’t you say? https://t.co/NEQuyZYSRn
@SharonandGlenn @FactsAreGood @komradeperogie @drdagly https://t.co/WcdbXJApXk Please don’t lie
RT @nickmmark: @zacroBID They did. ACTT1 published in @NEJM. Mortality wasn’t the primary endpoint but they found a similar effect size: 6.…
@zacroBID They did. ACTT1 published in @NEJM. Mortality wasn’t the primary endpoint but they found a similar effect size: 6.7% vs 11.9% mortality. It didn’t *quite* hit significance overall Pharma has resources but they only do the studies they need to get approved https://t.co/W9O8rDDFTe https://t.co/oysrVvOWmH
@Donniesgirl73 @RepMTG Shortly after the announcement of COVID, the patent holders announced a promising product. The trial didn’t compare to patent expired standard of care. Instead compared to only placebo. Of course some treatment is better than none. https://t.co/Sssbx378ek
@w_s_gosset @Louwrens911 @unguenta @NickHudsonCT @SpartacusHODL https://t.co/f8HSknEpVd https://t.co/8UqV8GccOa
@SMACar73 @CrowMagnumMan3 @JasonZacharyTN https://t.co/KXvXIZrWIY
@scumbunker @ladies4pd @ed_unwa https://t.co/8UqV8GccOa Just ignoring this now? Source the paper or admit you lied.
RT @davideyoungmd: @SassyGirlD1 @handmadekathy @IainMulady @doritmi @JCDeardeuff @TruthTwt @Izzitreally2 @Jccalmond2 @Monstercoyliar @krebi…
@WilliamKittel5 Conclusions: Our data show that Remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Nov 2020 https://t.co/odIk9z3HYz https://t.co/ip9iBeqYno
RT @carl_jurassic: @WilliamKittel5 Yup. Lots of people worked on that remdesivir study https://t.co/J4n93Fx5F8
@WilliamKittel5 Yup. Lots of people worked on that remdesivir study https://t.co/J4n93Fx5F8
@CaptainMedical @Chuck_Saucisse_ @JJBourdin_off @andrebercoff Commentez moi cet article @CaptainMedical Dites moi ce qu'il conclue... Si vous répondez vous allez en somme dire exactement la même chose que K Lacombe.
@CaptainMedical @Chuck_Saucisse_ @JJBourdin_off @andrebercoff Etes vous médecin oui ou non? Pas de réponse mhmm?
@Chuck_Saucisse_ @CaptainMedical @JJBourdin_off @andrebercoff Non regarde à nouveau la vidéo... Je sais c'est long et difficile de se concentrer plus de 3 minutes pour vous. Elle mentionne cet essai sans contrôle puis ce RCT ci dessous ⬇️⬇️ https://t.co/TBPvGZ7wMJ
@Chuck_Saucisse_ @CaptainMedical @JJBourdin_off @andrebercoff Il y a 2 min vous ne saviez même pas ce qu'est un RCT. Dans cette interview elle discute les résultats d'un RCT qui est le suivant ⬇️⬇️ Renseignez vous bordel. Vous êtes idiot et ça commence vraiment à se voir. https://t.co/TBPvGZ7wMJ https://t.co/vnljK0e9ZL
@LeCandideRaton @ThomasH71486271 @silvano_trotta c'est faux. Ils l'ont autorisé, d'une part car les essais in vitro étaient concluants, et d'autre part car les résultats d'une étude préliminaire étaient positifs. Dans l'urgence on n'attend pas un ans que la totalité des études soient finies https://t.co/Hw9tyAxFC9
@CheMarieBowles1 @ElonSimp35 @CitizenFreePres https://t.co/iRA9RBnm9K
Fellow #IDMedED with throwback #IDJournalClub
Remdesivir for the Treatment of Covid-19 - Final Report PMID: 32445440 https://t.co/awklsFZWs0
@VermeulenHellen @KeesVermeeren @wjmspaan @IGJnl Hier: https://t.co/LFmBlLnI79
@TsugawaYusuke 本物の素人ですみません．教えていただけないでしょうか．このNEJMの論文に，差の95%CIとは別に治療群と対照群の95%CIが記載ありますが，下名はこれは母集団の区間推定と思っていました．どう解釈するのが正しいのでしょうか？ https://t.co/WgcWY66PNk
@HealingCrone @richardursomd Hi, Carol.
Day 19 #66DaysOfData - Read research paper on Remdesivir for the Treatment of Covid-19 - Not only they have used point estimate also they have provided confidence interval of the days of treatment by using remdesivir. - Great way to learn Data Analytics! https://t.co/t0qNttODJI
Remdesivir for the Treatment of Covid-19 — Final Report | NEJM https://t.co/7uvm1DqaNb
@MMontclairre https://t.co/QvQECq67fe
@kotosquito We have definitive studies. They demonstrate efficacy and safety. https://t.co/UXyyp9lgfd https://t.co/rJDMGY1nlM So you're wrong. And yes, that sounds paranoid. Steroids. Off label. Approved.
@chedca @HealthySaneBE @matt_quantum @cappuccino64 https://t.co/doh1LJKmNm
@Diar380 @TonyBaduy @pompili_amanda @raouldukeerik @PremierImproves @mpc_xetts @JonathanHannah @ogilville1 @andylumm @Monstercoyliar @e4n44 @mcfunny @ShockTraumaNP @WendyOrent @malo_j @JimeeLiberty @skepticalprune @Nockit1 @Willard1951 @volpiranyas @AspAlaAsnAsnTyr @Tryingmypatient @ZaynJaffer @kath2cats @PLHartungRN @chimera414 @spoonsterboss1 @AndrewLazarus4 @PiattPicks @Fannyi5 @doom37455413 @richykirsh @tatsandfats @provaxtexan @sammy44231 @NoMisinfoToday @SallyJiggles @zeetubes @DPirate2020 @SkepticalMutant @Alex_on_A14 @MarkTho29550016 @Donutmindme1 @Tertianship @ali_nicholson_ @luther_snell @Hold2LLC @JonEmerick1 @mooonchild85 @AstraZeneca ACT-1 is the study which apparently peaked Faucis interest. https://t.co/D5izM6bZBX Effective, safe and... worse renal outcomes in placebo group
@MagickalG @Tryingmypatient
RT @FrankDElia7: @EstesPga @SkepticalMutant @provaxtexan @crabb_vicki @WendyOrent @CharlieGordon20 @CoralBlob @slemar_ @CallMeEOnly @Top_Mu…
@EstesPga @SkepticalMutant @provaxtexan @crabb_vicki @WendyOrent @CharlieGordon20 @CoralBlob @slemar_ @CallMeEOnly @Top_Muppetries @DCGreenZone1 @LiamKav @volpiranyas @i_am_joli_anne @AGoldsmithEsq @mcfunny @GMACVHHH @Suesue2point0 @RadRyderX @_mamadeb @AndrewLazarus4 @quigley_jesse @quesnel_john @ghoppe @wendy_Lynnette @Monstercoyliar @clownworld_bobo @TakethatCt @ZaynJaffer @Mchael21592783M @JustPlaying2Win @tenebra99 @gobantwo2 @melissa94307909 @MdRisette @doritmi @stevenmosher @Kathmarval @JawKneeFaiv @MickusDickus @policing_uk @BrockKrause @dodi_rains @carlsmythe @RenfieldThomas @TonyBaduy @ncdave4life @indyymac @Kolyin @diederikdk This is a study of remdesevir https://t.co/YhRabjU6DG Let us know when you or acne-treater Ardis find some. Here’s another https://t.co/v1DJOo83dA
@GavrielyRan @DavidBCollum https://t.co/OWdBB3Bv3O
@Pinkagogogirl @Navysports123 @DrScottHadland We actually do. Hence why we care for patients using the most up to date (not WHO recommendations from 2020) evidence based medicine, and not the incorrectly interpreted confirmation biased source data you find on Google. https://t.co/MsDKZtumhx
@TiinaHannelen @Kirsi71480173 @franttila @lissukkaa @MariaNordin tällä tavalla https://t.co/dxIt5FjQfg
RT @nickmmark: In #ACTT1 RDV did improve outcomes on an ordinal scale, but the effect was modest. It shortened time to clinical improvement…
In #ACTT1 RDV did improve outcomes on an ordinal scale, but the effect was modest. It shortened time to clinical improvement but not hospital LOS (patients stayed in the hospital longer to receive it). RDV did NOT improve mortality or risk of IMV. https://t.co/yGseeo3dNd 3/ https://t.co/D8If31k9Kv
@samthom82 @TeaPainUSA 2) WOnderful remdesivir https://t.co/LboPQa6Uix
That’s because of ACTT-1 (2020), but the data is ehhhh no found mortality benefit just “shorter time to recovery than patients in the placebo group” (10 vs 15 days; P<0.001) . https://t.co/cQ0ylqB26w . 3/n
The first Remdesivir trial was the ACTT-1. It favoured Remdesivir over placebo. https://t.co/RxOj7lsm2H
@chriske52963146 Link to this report: https://t.co/Fp8BW5cbYo
@jrseihgstein @Sq178kin @RGaugry @STEFXAV2 @ImmortelleXIII @SuisNadege @BobDena35658179 @f_philippot https://t.co/OhHnwZI3x8 https://t.co/CGkiH66DPe
@EllyD18 @BerthaKolker @MarcVegt @Noster20240123 Kan ook geld steken in behandeling??? Er zijn al redelijk wat onderzoeken die tonen aan dat er behandelingen zijn die effectief zijn. Hier is er een van. Als je meer wilt weten zou ik zeggen pubmed afzoeken. https://t.co/bo8JhSjdo6
@BKhoshnevisan @agha_mohamad1 این کلینیکال تریاله https://t.co/gNb8JT8Zpr
@eddy_terstall https://t.co/bo8JhSjdo6 https://t.co/OqffJQqBxl https://t.co/G4ZtvJaDJG Wetenschap is niet links of rechts. middelste heeft het over ivermectin. Er is veel positief resultaat met behandeling met verschillende reeds langdurig gebruikte medicijnen. Snap de verwarring bij mensen
https://t.co/eMbp6aoNCK https://t.co/sWmF6Dskbf
https://t.co/r8kU9rJNOx
@Robert39976069 @MichaSeweryn6 @Rafa93206709 poczytaj https://t.co/Jgg0pdmebL
Source of the NEJM final report: https://t.co/aY9IRLVept Remdes is also quite expensive, usually going on the thousands of pesos per vial.
RT @kazuchancocone: @catdqx NIHのACTT1の結果が4月29日にプレスリリースされ5月1日に米が承認、そして1週間後には日本で使用可となっています。「プレスリリース」ですよ？ただの「プレスリリース」 正式な Final Report は10月8日付…
RT @kazuchancocone: @catdqx NIHのACTT1の結果が4月29日にプレスリリースされ5月1日に米が承認、そして1週間後には日本で使用可となっています。「プレスリリース」ですよ？ただの「プレスリリース」 正式な Final Report は10月8日付…
@catdqx NIHのACTT1の結果が4月29日にプレスリリースされ5月1日に米が承認、そして1週間後には日本で使用可となっています。「プレスリリース」ですよ？ただの「プレスリリース」 正式な Final Report は10月8日付になってました。 最終的な報告を待たず承認しちゃっていいんですか？ https://t.co/6Jz8Lj5spi https://t.co/lqYyjrK3Qs
@BrendaCrabtreeR Esta es la ficha de registro del ACTT1 https://t.co/ne3UC4raU8 Autorizado el 31 de marzo. Terminado. https://t.co/9LMX8gI3QL Publicado el 8 de octubre https://t.co/rBXJE3Ervb
RT @Dr_JMLV: @JorgeBustos1 Estudio PREclínico (esto es, no con pacientes, sino con cultivos celulares) que SOLO afirma que plitidepsina log…
@JorgeBustos1 Estudio PREclínico (esto es, no con pacientes, sino con cultivos celulares) que SOLO afirma que plitidepsina logra el mismo efecto que remdesivir, aunque con dosis MENORES. Bien, pero conviene subrayar que la eficacia del comparador es más bien pobre: https://t.co/x9rdjWBKg8
Remdesivir for the Treatment of Covid-19 - Final Report https://t.co/7NpUoIUe5C
RT @idevisch: Ter info aan alle politici die plots zelfverklaarde Remdivisir-specialisten zijn geworden: misschien dit even lezen ipv HLN?…
RT @idevisch: Ter info aan alle politici die plots zelfverklaarde Remdivisir-specialisten zijn geworden: misschien dit even lezen ipv HLN?…
Ter info aan alle politici die plots zelfverklaarde Remdivisir-specialisten zijn geworden: misschien dit even lezen ipv HLN? https://t.co/2nA9PLccCu
@QuackFighter @APHP @MartinHirsch https://t.co/hJQeFQGzOa
John H. Beigel, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020; 383: 1813-1826 https://t.co/Jn1x6vRKMP
Remdesivir superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Remdesivir for the Treatment of Covid-19 — Final Report @NEJM @NEJMGroup @NEJMres360 https://t.co/AeXjtzRUVr
https://t.co/R7JZ5Jugxr Introducing the basic info on #treatments and #vaccine for #COVID19 #science #medicalcommunication
続き➾有意差はなかった（1.20：0.94-1.52） 。Final Report NEJM Remdesivir for the Treatment of Covid-19 The New England Journal of Medicine: Research & Review Articles on Disease & Clinical Practiceより（だいぶ部分的に・・）抜粋。 https://t.co/2cOCjbney5
RT @drantonioquispe: "Rendesivir: Terapia para COVID-19 severo" Según el trial ACTT-1 tratar COVID-19 severo con remdesivir disminuye la m…
RT @drantonioquispe: "Rendesivir: Terapia para COVID-19 severo" Según el trial ACTT-1 tratar COVID-19 severo con remdesivir disminuye la m…
"Rendesivir: Terapia para COVID-19 severo" Según el trial ACTT-1 tratar COVID-19 severo con remdesivir disminuye la mediana de tiempo de recuperación de 15d (IC 95%: 13-18) a 10d (IC 95%, 9-11), comparado con placebo (ITR, 1,29; IC 95%: 1,12-1,49) https://t.co/T8JbMCUnU4 https://t.co/hMz48UFyWC
RT @UTSWPedsCCM: Journal club today: Third year fellow Molly McGetrick @McgetrickMd leads us through updates on remdesivir trials, with som…
Journal club today: Third year fellow Molly McGetrick @McgetrickMd leads us through updates on remdesivir trials, with some EBM pearls on Kaplan-Meier curves included as well. We're all eagerly awaiting the pediatric data... #PedsICU https://t.co/WGBAPgXAvN
Remdesivir for Treatment of #COVID19: Final Report. “The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). https://t.co/g6qNg0etZY
https://t.co/dMBhdUkz0Y
~link for the nonbelievers~ published in NEJM
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
@Dan_Donovan_17 @vanleek555 Since you asked https://t.co/6GpdsHSkKh
9/17 De eerste resultaten kwamen een tijdje terug al uit het RECOVERY-project, waarbinnen ook dexamethason en de combi lopinavir-ritonavir zijn onderzocht. Remdesivir leidde niet tot een verschil in sterfte. Wel herstelden mensen ±5 dagen sneller. https://t.co/sbZWZenbbU
Patients hospitalized with COVID-19 had a faster recovery time and a non-significantly lower risk of death if they took Remdesivir (9/18) https://t.co/t82m2N66TP
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
Remdesivir for the Treatment of Covid-19 — Final Report https://t.co/ixuNabrivx
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
2020/10/8 全論文デイリーランキング 1位
5 day reduction in recovery time: Remdesivir for the Treatment of Covid-19 — Final Report | NEJM https://t.co/OQua4fLAkT
RT @heshnarayanan: #Remdesivir for the Treatment of #Covid19 @NEJM https://t.co/vKumNBzpwa https://t.co/6A1JchsBfe
#Remdesivir for the Treatment of #Covid19 @NEJM https://t.co/vKumNBzpwa https://t.co/6A1JchsBfe
Remdesivir for the Treatment of Covid-19 — Final Report | NEJM https://t.co/r3Yq3qDy4D
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
Resultados finales del ensayo ACTT-1 Remdesivir vs Placebo. No diferencias en la mortalidad a 29 días. Menor tiempo de recuperación. https://t.co/2pmYA1lu3v https://t.co/V7hVkAtAuM
RT @waltercurioso: A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median…
A RCT published in @NEJM: Patients hospitalized with #COVID19 in the remdesivir group had a faster recovery time (median 10 vs. 15 days) and a non-significantly lower risk of death at 29 days (HR=0.73, 95% CI 0.52-1.03) than patients in the placebo group https://t.co/GrdYeNyEZu
In an RCT of the antiviral drug remdesivir, patients hospitalized with COVID-19 in the remdesivir group had a faster recovery time (median 10 vs. 15 days) and a non-significantly lower risk of death at 29 days than patients in the placebo group. https://t.co/zevGfU0xK2
RT @deepakdeepak: COVID 19 AND PRESIDENT DONALD TRUMP https://t.co/YARMvCvppU via @YouTube @realDonaldTrump should recover fully and fast b…
@MarkHoofnagle @davideyoungmd @gorskon https://t.co/Ui8OY4D8mN https://t.co/kJjRqqQxdM
COVID 19 AND PRESIDENT DONALD TRUMP https://t.co/YARMvCvppU via @YouTube @realDonaldTrump should recover fully and fast because of swift administration of 2 different antivirals.@PMOIndia @AmitShah @joerogan @piersmorgan @svaradarajan @PrannoyRoyNDTV
Remdesivir for the Treatment of Covid-19 — Preliminary Report | h/t @celinegounder https://t.co/UZlRrmLanW https://t.co/bChTR9t3cq
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @NeilFlochMD: The drug that @realDonaldTrump Is now taking: #Remdesivir for the Treatment of Covid-19 - has shown improvement of symp…
RT @NeilFlochMD: The drug that @realDonaldTrump Is now taking: #Remdesivir for the Treatment of Covid-19 - has shown improvement of symp…
The drug that @realDonaldTrump Is now taking: #Remdesivir for the Treatment of Covid-19 - has shown improvement of symptoms in randomized trials @NEJM #covid19 https://t.co/d12aFoHxRn
Importantly, recovery within 30 days is nearly 100% for patients receiving Remdesivir but are not receiving oxygen. Should oxygen be required or ventilation, outcomes begin to drop. 3/https://t.co/KLSFCfvyb9 https://t.co/4ulsMwLzbP
Remdesivir for the Treatment of Covid-19 - Preliminary Report - PubMed https://t.co/KLSFCfvyb9
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
RT @CharlesBHolmes: Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median…
Another multinational trial of >1000 patients found that remdesivir was associated with faster time to recovery (median 11 vs 15 days w/placebo) in COVID patients with pulmonary involvement. 9/n https://t.co/hz8It1DmcJ
6/ Prior trials 1/2 i) Remy shortens recovery time in sickest pts (11d median vs 15) - https://t.co/0gD2E4xHdo - Sickest (SpO2 <94% RA, on Vent of Non-invasive-vent ~ at #6 above) :) double-blinded :( prelim results [is there final?], no mortality benefit at 15d
RT @FarmaCHUAC: Esta semana nuestra compañera @carladeoliva nos presentó los resultados preliminares del Adaptive Covid-19 Treatment Trial…
RT @FarmaCHUAC: Esta semana nuestra compañera @carladeoliva nos presentó los resultados preliminares del Adaptive Covid-19 Treatment Trial…
Esta semana nuestra compañera @carladeoliva nos presentó los resultados preliminares del Adaptive Covid-19 Treatment Trial (ACTT-1) https://t.co/D0fTMyfjD0 https://t.co/7xcBtMotdC
RT @UMMSLibrary: And the highest Altmetric score @UMassMedical goes to
And the highest Altmetric score @UMassMedical goes to
@misterchambo @richardursomd Dr 007 missed that point. He also missed the ACT1 study: https://t.co/rCBtMfWu1z
@maryforbus @richardursomd @Peace_Creep Guess Dr 007 missed that part and didn’t read the ACT1 study. This JAMA study is inconclusive. Want the original ACT1 proposal that Fauci sent me if it helps. https://t.co/rCBtMfWu1z
RT @ERIC_F_FABRE_M: https://t.co/RrHJ2fQ46T https://t.co/XDR5CnQ4RR
https://t.co/RrHJ2fQ46T https://t.co/XDR5CnQ4RR
Remdesivir for the Treatment of Covid-19 - Preliminary Report https://t.co/p8Tox7ErW6
@yeittu @SatishKTM NEJM maa aayeko yo ACTT-1 study ko prelim data maa chai Remdesivir vs placebo maa better time to recovery Remdesivir ko chha. Yo chai double-blind, RCT ho of 1059 pts. Mortality benefit ta esle pani dekhako chaina hai. Final results kaile publish hola. https://t.co/unqf655QfP
@OrlandoRPN https://t.co/j3swTEdZgm
@bodhibrian @Le_Nautonnier @MathesVamer @drsimonegold @JAMA_current Never suggested that. Question is whether HQC works with or w/o Zn and what are endogenous levels of Zn in vivo. Remdesivir more specific inhibitor of RNApol. Understand the science: https://t.co/rCBtMfWu1z
@AndreasShrugged @pjanik_otm @ScottAdamsSays Ah, thanks, because your suggestion made me look closer, and there is a NEJM study that similarly shows an improved recovery time, the 95% CI are 9 - 12 days with REM and 13-19 with placebo. The Lancet study did not show significance, this one does. https://t.co/N9UTrykHwZ
@raoult_didier @elonmusk @raoult_didier @JamesTodaroMD @drsimonegold compounds can work in in vitro but not in vivo. What is the endogenous levels Zn in body? I will dox you guys! https://t.co/rCBtMfWu1z https://t.co/0A7HTE8oBL
RT @TheDrugProject_: 3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demost…
RT @TheDrugProject_: 3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demost…
RT @TheDrugProject_: 3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demost…
RT @TheDrugProject_: 3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demost…
RT @TheDrugProject_: 3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demost…
RT @TheDrugProject_: 3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demost…
3) Remdesivir: Profármaco que bloquea la replicación del #coronavirus al inhibir la ARN polimerasa viral. Ha demostrado ser eficaz en pacientes que requieren oxígeno suplementario, reduciendo la mortalidad y la convalecencia de 15 a 11 días.
@Sid2001 @kkmick19 @AdamHykes @JamesTodaroMD Please do a Pubmed search. Studies: https://t.co/rCBtMfWu1z
@Cryssylol @bdelloid @IsabelOtt There are many safe therapeutics that disrupt replication which don’t cause protein aggregation; remdesivir toxic studies were done in Ebola clinical trials then recently Covid19 trials: https://t.co/rCBtMfWu1z
@maromero86 @petrogustavo Porque en este estudio no redujo mortalidad, solo días de hospitalización. https://t.co/cpH43HLYO1
@lewistlc @nicolelynnann @kksheld Lmao I didn’t say anything about remdesivir but you clearly didn’t read that paper either! Acute renal failure was just as (if not more) common w/ placebo. At least it was a real placebo controlled RCT https://t.co/HPXrvGJK3Z https://t.co/VhpNPTfDRo
Does #remdesivir shorten time to recovery compared to placebo? The following article discusses the finding of a study investigating the use of Remdesivir to treat #COVIDー19 #MedTwitter https://t.co/kP1lbUmeRf https://t.co/7Cyi9N6SXe
Resultados de estudo randomizado com grupo controle com placebo, demonstrou que o remdisivir demonstrou redução no tempo de recuperação em pacientes com formas moderadas e graves da COVID-19 (https://t.co/ghrELCHEtb). Este medicamento ainda não tem registro no Brasil. +
@wargonm Une étude qui conclut à une réduction de la durée d’hospitalisation de 4 jours. Rien d’extraordinaire pour un médicament si cher. https://t.co/LwF0q7TfX5
@stavmar @HeavnerPharmD Prelim report: https://t.co/zlPmZ20viL. Note that it's prelim b/c many patients hadn't had Day 29 visit on Apr 27 (when DSMB reviewed the data), but last pt enrollment was Apr 22. That means they had completed all Day 29 visits by May 22. One would hope to see final data soon...
@Atul_Gawande @nutrmom I'm not reading all this thread...but I am gobsmacked at claims here that, the work on Dexamethasone treatment for accute COVID19 infection, wasn't science, the scientific method was not being observed...etc.. in response to publication of the science. https://t.co/Ai1PPMptKM
#Remdesivir provides a clinically/statistically significant reduction in the duration of symptoms of #COVID19 . Questions remain regarding its effects on mortality and on patients who have advanced disease that requires mechanical ventilation or ECMO. https://t.co/0N60KhBk8X
RT @diaz_cid: Les dejo el informe preliminar Remdesivir para el tratamiento de Covid-19. https://t.co/aQAAp59WlL
RT @diaz_cid: Les dejo el informe preliminar Remdesivir para el tratamiento de Covid-19. https://t.co/aQAAp59WlL
Les dejo el informe preliminar Remdesivir para el tratamiento de Covid-19. https://t.co/aQAAp59WlL
@Ammer_B Finally found it: https://t.co/dVlpwQEzzK
Remdesivir for the Treatment of Covid-19 — Preliminary Report | NEJM https://t.co/M8HXpr5TuZ
RT @Rodrigo_G_I: Interesting new finding. Remdesivir for the Treatment of Covid-19 — Preliminary Report | NEJM https://t.co/DmYaLDL24r
Interesting new finding. Remdesivir for the Treatment of Covid-19 — Preliminary Report | NEJM https://t.co/DmYaLDL24r
@NatureNews Here is the original article: Remdesivir for the Treatment of Covid-19 — Preliminary Report https://t.co/iOJgEQaX0d
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
#Remdesivir shortens recovery time by ~26% in hospitalized patients with #COVID19 and lower respiratory tract infections. Incidence of serious adverse events was reduced by ~6%. https://t.co/6AWQ0CL5OW
RT @ZapateroAntonio: Remdesivir mejora el tiempo de recuperación en pacientes con oxígeno suplementario, no en intubados.Disminución de mor…
An article published in New England Journal of Medicine shows that #Remdesivir shortened hospital stay and time to recovery by several days. https://t.co/C9PHQSVcND
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
コロナにレンデシビルが効く。 John H. Beigelらが合計1063人の患者に無作為にレムデビル、またはプラセボのいずれかを投与して、回復までの時間の短縮をはかった。 結果レンデシビルはプラセボよりも優れてた。 コロナの治療の救世主レンデシビルになるか？ https://t.co/Z2dkNDWG9e
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
RT @ATSCritCare: Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V wit…
Does #remdesivir benefit those hospitalized with #covid__19? We discuss the @NEJM publication https://t.co/BvWLEDcQ4V with 1st author Dr John Beigel @NIAIDNews #COVID19 We learned a lot!!
Trending on PubMed: Remdesivir for the Treatment of Covid-19 - Preliminary Report. https://t.co/oXo4eoqGRz
Trending on PubMed: Remdesivir for the Treatment of Covid-19 - Preliminary Report. https://t.co/T8coE4YmCp
Remdesivir for the Treatment of Covid-19 - Preliminary Report https://t.co/7z3LvtJFuI @NIAIDNews Is there a #covid19 treatment on the horizon? An exciting prospect, results reported in @NEJM
RT @ZapateroAntonio: Remdesivir mejora el tiempo de recuperación en pacientes con oxígeno suplementario, no en intubados.Disminución de mor…
Remdesivir for the Treatment of Covid-19 - Preliminary Report - PubMed https://t.co/viM2U1VmQu
RT @PubTrend: Trending on PubMed: Remdesivir for the Treatment of Covid-19 - Preliminary Report. https://t.co/bKhiK4g2Ws
RT @Tati_Policarpo: Great noon conf review of @NEJM #Remdesevir article by @ChidaNatasha & Colin. Interesting point that was highlighted: n…
Trending on PubMed: Remdesivir for the Treatment of Covid-19 - Preliminary Report. https://t.co/bKhiK4g2Ws
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
RT @geiger_warning: 【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発…
【ひとりごと】レムデシビルの効果発表 結論→重症化の人にはイマイチだが、それ以外早く治る効果あり！ アビガンよりレムデシビルの臨床試験は進んでおり効果があることが分かったそうです。アメリカの発表であるのと臨床試験数が少ないので他国の発表を期待してます https://t.co/XpSjs17UDD
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
RT @NATROM: 二重盲検プラセボ対照ランダム化比較試験。成人のCOVID-19入院患者が対象。レムデシビルを投与すると、プラセボ対照と比較して、回復までの時間が早い（11日間対15日間）[ https://t.co/0bKHHPDmiL ]。
Nutshell #24: Study with more than 1000 #COVIDー19 patients concludes that #remdesivir significantly shortens time to recovery in adults with lower respiratory tract infection. From @NIAIDNews in @NEJM. Article: https://t.co/mWCj0EzfzS #SARSCoV2 #coronavirus #research #Science https://t.co/dtB95xeqVx
RT @kidney_boy: brilliant video on remdesiver by @DrEricStrong. Great production and clear explanations. https://t.co/Qw873tsN5w
Remdesivir for the Treatment of Covid-19 — Preliminary Report | NEJM https://t.co/abujzlBfUg https://t.co/Cyy6jWdNYJ
RT @kidney_boy: brilliant video on remdesiver by @DrEricStrong. Great production and clear explanations. https://t.co/Qw873tsN5w
Will Remdesivir Save The World From COVID? https://t.co/B8gF7VcHAW
RT @kidney_boy: brilliant video on remdesiver by @DrEricStrong. Great production and clear explanations. https://t.co/Qw873tsN5w
brilliant video on remdesiver by @DrEricStrong. Great production and clear explanations. https://t.co/Qw873tsN5w
ICU https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
meaningful. https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?source=nejmfacebook&medium=organic-social#.XshRQ1KoDwx.twitter
https://t.co/KzKZ7iw8HX
@jimcramer This video CASTS DOUBT on effectiveness of Remdesivir!! https://t.co/mKb2H4Y1BS
Nailed it, @DrEricStrong. The funniest bet is @GileadSciences' 5 vs 10 days of #Remdisivir with no control, as if the drug is an absolute winner! It didn't even work against Ebola, which it was developed for! Bizzar times for evidence based medicine!!! https://t.co/EpGezDXBx5
The Fauci-touted remdesivir study was poorly done, tried to conceal deaths caused by the drug, and may have been intentionally rigged to get the desired result: https://t.co/YKIbV9JpQz https://t.co/J4pAM7Zv5o https://t.co/DP6789twxu https://t.co/dftYQtKibb https://t.co/bggVGmNedX
https://t.co/J9kv02AGnX
Summary of new data published in lancet and 1 trial info given by gillead on remdesivir .... @PMOIndia @drharshvardhan https://t.co/Q9Pq2NCSmn
Remdesivir did NOT work well on #COVID19 - can't believe BS in media #VOTEBLUE 4 DECENCY Dump GOP Senators #Farmers #Education #TeaParty #AARP #Veterans #MeToo #GenX #Millenials #marchforourlives #1u #MAGA #Independents #Indigenous #P2 #Latinx #BLM #LGBTQ https://t.co/LsgZDsGGTM
XP
JC
JR
AC
H
J
دا
F
EP